Immuneed
Immuneed AB is dedicated to accelerating the development of safer medicines through innovative whole blood analysis technology. They provide human-relevant immunological assessments for preclinical-stage molecules, supporting drug developers in understanding immune responses triggered by candidate drugs. Their unique ID.Flow® technology enables real-time, physiologically relevant analysis of immune responses in circulating human blood, aiding in de-risking first-in-human studies and meeting regulatory requirements. The company collaborates with biotech and pharma innovators worldwide, offering services that analyze immune cells, complement system, cytokines, platelets, and immunoglobulins to generate precise, human-relevant data for safer drug development.
Industries
Nr. of Employees
small (1-50)
Immuneed
Products
Circulating fresh whole-blood assay platform
A platform that circulates fresh human whole blood with test substances at controlled physiological conditions to generate integrated immunological, complement and hemostasis readouts for preclinical assessment.
Circulating fresh whole-blood assay platform
A platform that circulates fresh human whole blood with test substances at controlled physiological conditions to generate integrated immunological, complement and hemostasis readouts for preclinical assessment.
Services
End-to-end testing using circulating fresh human whole blood collected on site, assessing integrated immune, complement and hemostasis responses to test articles.
Sensitive cytokine release testing in minimally manipulated fresh whole blood to predict systemic inflammatory potential of drug candidates.
Simultaneous evaluation of antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in fresh whole blood to capture interacting effector mechanisms.
Assessment of complement activation markers and functional inhibition in active whole blood to detect CARPA risk and pathway-specific effects.
Functional assays in fresh whole blood measuring platelet activation, aggregation, conjugates and counts to assess prothrombotic and inflammatory risk.
Phenotypic and functional profiling of leukocyte subsets in whole blood to evaluate cellular activation, depletion and effector signatures.
End-to-end testing using circulating fresh human whole blood collected on site, assessing integrated immune, complement and hemostasis responses to test articles.
Sensitive cytokine release testing in minimally manipulated fresh whole blood to predict systemic inflammatory potential of drug candidates.
Simultaneous evaluation of antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in fresh whole blood to capture interacting effector mechanisms.
Assessment of complement activation markers and functional inhibition in active whole blood to detect CARPA risk and pathway-specific effects.
Functional assays in fresh whole blood measuring platelet activation, aggregation, conjugates and counts to assess prothrombotic and inflammatory risk.
Phenotypic and functional profiling of leukocyte subsets in whole blood to evaluate cellular activation, depletion and effector signatures.
Expertise Areas
- Whole blood-based immunotoxicity assessment
- Complement system evaluation and complement inhibition testing
- Cytokine release and infusion reaction prediction
- Antibody effector function assessment (ADCC/CDC) in human blood
Key Technologies
- Circulating whole-blood loop assay
- Flow cytometry for whole-blood samples
- Multiplex cytokine assays
- Functional ADCC/CDC assays
News & Updates
A reflection on 2021 achievements and plans for 2022, including laboratory expansion and international growth.
Summary of milestones and successes in 2022, including laboratory move, team expansion, and market reach.
An overview of the challenges and importance of assessing complement activation in preclinical drug development, including the risks of hypersensitivity reactions and thrombosis.
Discussion on the importance of proper testing of complement inhibitors, the pathways involved, and the advantages of whole blood assays for accurate assessment.
Exploration of how whole blood assays provide a more accurate representation of in vivo immune responses, aiding in toxicity prediction and dose selection.
A reflection on 2021 achievements and plans for 2022, including laboratory expansion and international growth.
Summary of milestones and successes in 2022, including laboratory move, team expansion, and market reach.
An overview of the challenges and importance of assessing complement activation in preclinical drug development, including the risks of hypersensitivity reactions and thrombosis.
Discussion on the importance of proper testing of complement inhibitors, the pathways involved, and the advantages of whole blood assays for accurate assessment.
Exploration of how whole blood assays provide a more accurate representation of in vivo immune responses, aiding in toxicity prediction and dose selection.